2024 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2024)
San Francisco, California, US 25 January 2024 - 27 January 2024
Nivolumab plus ipilimumab superior to sunitinib in advanced RCC
First-line treatment with nivolumab plus ipilimumab (NIVO+IPI) results in better survival and response benefits in patients with advanced renal cell carcinoma (aRCC) when compared with sunitinib (SUN), as shown by long-term follow-up data from the CheckMate 214 trial.
Pembrolizumab plus lenvatinib effective against nonclear cell RCC
Pembrolizumab (pembro) plus lenvatinib (lenva) provides durable antitumour activity in patients with advanced nonclear cell renal cell carcinoma (nccRCC) and has a manageable safety profile, according to the results of the phase II KEYNOTE-B61 study.
TKI-ICI combo offers hope for prostate cancer patients with poor prognosis
A combination of the TKI* cabozantinib and ICI** atezolizumab improved progression-free survival (PFS) in men with metastatic castration-resistant prostate cancer (mCRPC) with measurable extrapelvic nodal or visceral metastasis who progressed on prior novel hormonal therapy (NHT), findings from the phase III CONTACT-02 trial have shown.
Adjuvant pembrolizumab holds promise in bladder cancer
The phase III AMBASSADOR Alliance A031501 trial showed a statistically significant and clinically meaningful improvement in disease-free survival (DFS) with adjuvant pembrolizumab compared with observation in patients with high-risk locally advanced muscle-invasive urothelial carcinoma (MIUC) after radical surgery regardless of PD-L1 status.
